DEFY

EXPECTATIONS

Challenge treatment goals

NOW APPROVED

Ankylosing Spondylitis

for adult TNFi-IR patients

Ulcerative Colitis

for moderate to severe adult TNFi-IR patients

Atopic Dermatitis

for moderate to severe patients 12+ years not adequately controlled with other systemic drug products, including biologics

Psoriatic Arthritis

for adult TNFi-IR patients

 

RHEUMATOLOGY

for moderate to severe adult TNFi-IR patients

NOW APPROVED

for adult TNFi-IR patients

NOW APPROVED

for adult TNFi-IR patients

Limitations of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.

 

DERMATOLOGY

NOW APPROVED

for moderate to severe patients 12+ years not adequately controlled with other systemic drug products, including biologics

Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

 

GASTROENTEROLOGY

NOW APPROVED

for moderate to severe adult TNFi-IR patients

Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and cyclosporine.

RINVOQ® Complete logo.

RINVOQ Complete offers patients the resources and support they need
to start and stay on track with RINVOQ as prescribed.

Questions? Call 1.877.COMPLETE
(1.877.266.7538)

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor.